ATE392213T1 - Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen - Google Patents

Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen

Info

Publication number
ATE392213T1
ATE392213T1 AT02718150T AT02718150T ATE392213T1 AT E392213 T1 ATE392213 T1 AT E392213T1 AT 02718150 T AT02718150 T AT 02718150T AT 02718150 T AT02718150 T AT 02718150T AT E392213 T1 ATE392213 T1 AT E392213T1
Authority
AT
Austria
Prior art keywords
gamma
inhibitors
treatment
degenerative diseases
chronic degenerative
Prior art date
Application number
AT02718150T
Other languages
English (en)
Inventor
Hans Weiher
Helmut Sies
Guenter Wagner
Original Assignee
Gtx Pharmaceuticals Gmbh
Hans Weiher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx Pharmaceuticals Gmbh, Hans Weiher filed Critical Gtx Pharmaceuticals Gmbh
Application granted granted Critical
Publication of ATE392213T1 publication Critical patent/ATE392213T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02718150T 2001-02-20 2002-02-20 Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen ATE392213T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01104063 2001-02-20

Publications (1)

Publication Number Publication Date
ATE392213T1 true ATE392213T1 (de) 2008-05-15

Family

ID=8176542

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02718150T ATE392213T1 (de) 2001-02-20 2002-02-20 Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen

Country Status (4)

Country Link
EP (1) EP1361885B1 (de)
AT (1) ATE392213T1 (de)
DE (1) DE60226126T2 (de)
WO (1) WO2002066047A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1602926A1 (de) * 2004-06-04 2005-12-07 University of Geneva Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758551A (en) * 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types

Also Published As

Publication number Publication date
EP1361885A1 (de) 2003-11-19
DE60226126D1 (de) 2008-05-29
EP1361885B1 (de) 2008-04-16
WO2002066047A1 (en) 2002-08-29
DE60226126T2 (de) 2009-05-07

Similar Documents

Publication Publication Date Title
EP1485381B8 (de) Azolylaminoazine als inhibitoren von proteinkinasen
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
WO2003080582A3 (de) Fredericamycin-derivate
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
DK1643999T3 (da) Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
MXPA04005809A (es) Inhibidores de proteinas quinasas.
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
ATE378053T1 (de) Pharmazeutische zusammensetzungen zur behandlung von nierenfunktionsstörungen
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
BRPI0410704A (pt) uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties